Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy

Documenti analoghi

• Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
  di: Fabian Falkenbach, et al.
  Pubblicazione: (2024)
• Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
  di: Takafumi Yanagisawa, et al.
  Pubblicazione: (2024)
• Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
  di: Shintaro Narita, et al.
  Pubblicazione: (2024)
• Impact of presentation timing in metastatic hormone‐sensitive prostate cancer: Characterization of patients and identification of prognostic factors
  di: Juliana Arenas Hoyos, et al.
  Pubblicazione: (2024)
• Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
  di: Mike Wenzel, et al.
  Pubblicazione: (2024)